Disease modification in inflammatory skin disorders: opportunities and challenges
T Bieber - Nature Reviews Drug Discovery, 2023 - nature.com
Progress in understanding of the mechanisms underlying chronic inflammatory skin
disorders, such as atopic dermatitis and psoriasis vulgaris, has led to new treatment options …
disorders, such as atopic dermatitis and psoriasis vulgaris, has led to new treatment options …
The role of IL-17 and anti-IL-17 agents in the immunopathogenesis and management of autoimmune and inflammatory diseases
SPDG Berry, C Dossou, A Kashif, N Sharifinejad… - International …, 2022 - Elsevier
Abstract Interleukin-17 (IL-17) is a proinflammatory cytokine involved in chronic inflammation
occurring during the pathogenesis of allergy, malignancy, and autoimmune diseases such …
occurring during the pathogenesis of allergy, malignancy, and autoimmune diseases such …
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double …
JF Merola, R Landewé, IB McInnes, PJ Mease… - The Lancet, 2023 - thelancet.com
Background Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin
(IL)-17F and IL-17A. This study compared the efficacy and safety of bimekizumab with …
(IL)-17F and IL-17A. This study compared the efficacy and safety of bimekizumab with …
Interleukin-17 family members in health and disease
SH Chung, XQ Ye, Y Iwakura - International immunology, 2021 - academic.oup.com
Abstract The interleukin-17 (IL-17) family consists of six family members (IL-17A–IL-17F) and
all the corresponding receptors have been identified recently. This family is mainly involved …
all the corresponding receptors have been identified recently. This family is mainly involved …
Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis
S Klint, J Feldwisch, L Gudmundsdotter… - MAbs, 2023 - Taylor & Francis
Psoriasis, an immune-mediated inflammatory disease, affects nearly 125 million people
globally. The interleukin (IL)-17A homodimer is a key driver of psoriasis and other …
globally. The interleukin (IL)-17A homodimer is a key driver of psoriasis and other …
Bimekizumab for the treatment of psoriasis: a review of the current knowledge
A Ruggiero, L Potestio, E Camela… - … : Targets and Therapy, 2022 - Taylor & Francis
Bimekizumab, a novel humanized monoclonal IgG1 antibody that neutralizes both IL-17A
and IL-17F, was recently approved the treatment of moderate to severe plaque psoriasis in …
and IL-17F, was recently approved the treatment of moderate to severe plaque psoriasis in …
Pathogenic role of IL-17 and therapeutic targeting of IL-17F in psoriatic arthritis and spondyloarthropathies
G Sánchez-Rodríguez, L Puig - International journal of molecular …, 2023 - mdpi.com
The interleukin 17 (IL-17) family, a subset of cytokines consisting of IL-17A-F, plays crucial
roles in host defence against microbial organisms and the development of inflammatory …
roles in host defence against microbial organisms and the development of inflammatory …
Bimekizumab for the treatment of psoriatic arthritis
Y Tanaka, S Shaw - Expert Review of Clinical Immunology, 2024 - Taylor & Francis
ABSTRACT Introduction Interleukin (IL)-17A and IL-17F have overlapping roles in pro-
inflammatory signaling and have been implicated in the pathogenesis of psoriatic disease …
inflammatory signaling and have been implicated in the pathogenesis of psoriatic disease …
Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE …
X Baraliakos, A Deodhar, D Van Der Heijde… - Annals of the …, 2024 - ard.bmj.com
Objectives Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits
interleukin (IL)-17F in addition to IL-17A, has demonstrated superior efficacy versus placebo …
interleukin (IL)-17F in addition to IL-17A, has demonstrated superior efficacy versus placebo …
RORγt inhibition ameliorates IL-23 driven experimental psoriatic arthritis by predominantly modulating γδ-T cells
C Mortier, E Gracey, J Coudenys, T Manuello… - …, 2023 - academic.oup.com
Objective Divergent therapeutic outcomes on different disease domains have been noted
with IL-23 and IL-17A-blockade in PsA. Therefore, elucidating the role of RORγt, the master …
with IL-23 and IL-17A-blockade in PsA. Therefore, elucidating the role of RORγt, the master …